Picture loading failed.

Pre-made Zolbetuximab benchmark antibody (Whole mAb, anti-CLDN18 therapeutic antibody, Anti-CD279/PD1/SLEB2/hSLE1 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Zolbetuximab (development code IMAB362) is an experimental monoclonal antibody against isoform 2 of Claudin-18. It is under investigation for the treatment of gastrointestinal adenocarcinomas and pancreatic tumors. IMAB362 was developed by Ganymed Pharmaceuticals AG.[1]

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-649-1mg 1mg 3090
GMP-Bios-ab-649-10mg 10mg Inquiry
GMP-Bios-ab-649-100mg 100mg Inquiry
GMP-Bios-ab-649-xmg >100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Pre-Made Zolbetuximab biosimilar, Whole mAb, Anti-CLDN18 Antibody: Anti-SFTA5/SFTPJ therapeutic antibody
INN Name Zolbetuximab
FormatWhole mAb
DerivationChimeric (Mouse/Human)
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2017
Year Recommended2018
CompaniesGanymed Pharmaceuticals
Conditions ApprovedHodgkin's disease
Conditions ActiveCervical cancer;Non-small cell lung cancer;Breast cancer;Cancer;Ovarian cancer;Pancreatic cancer;Solid tumours
Conditions DiscontinuedSolid tumours
Development Techna